Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Robin Kate Kelley et al.|NEJM Evidence|2022Cited by 1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398